Hengrui Pharma Shows Remarkable Revenue Increase in 2025
Hengrui Pharma (600276.SH; 01276.HK) has announced its revenue for the first three quarters of 2025 reached RMB23.20 billion. This figures represent an impressive 14.85% increase from the previous year. Moreover, the net profit attributable to shareholders surged to RMB5.75 billion, marking a significant rise of 24.50% compared to the same period last year.
Driving Innovation Through New Drug Approvals
Throughout this period, Hengrui secured the approval for one new medication in its pipeline, while actively pursuing progress with eight New Drug Application (NDA) submissions. Additionally, the company received 48 approvals for clinical trials, emphasizing its commitment to innovation in healthcare. Notably, four of its drug development programs earned a breakthrough therapy designation, showcasing the promising potential of its research endeavors.
Highlight of GLP-1/GIP Dual Agonist
Among the key developments, the GLP-1/GIP dual agonist HRS9531 demonstrated favorable Phase III topline results focusing on weight management. This advancement highlights Hengrui's focus on metabolic health and the strength of its late-stage assets, reinforcing its market competitiveness.
Significant Presence at Global Oncology Conference
At the recent ESMO 2025 held in Berlin, Hengrui made headlines by presenting findings from 46 oncology studies across 14 innovative programs. This included nine oral presentations, one of which gained significant recognition by being published in The Lancet. Their presence at this major global cancer congress marks a major milestone for Hengrui Pharma in showcasing their commitment to oncology research.
Strategic Collaborations and Licensing Deals
Additionally, Hengrui took a significant step forward by concluding three licensing agreements with multinational partners during the third quarter. These deals are estimated to exceed US$10 billion in potential transaction value, underscoring Hengrui's strategic initiatives in expanding its global footprint and operational capabilities.
Commitment to Global Growth and Innovation
Looking ahead, Hengrui Pharma aims to sustain its focus on advancing its homegrown research and development initiatives while enhancing its global commercial execution. This includes ensuring effective clinical development and establishing strategic partnerships to deliver innovative therapies that make a meaningful difference in patients' lives worldwide.
Frequently Asked Questions
What was Hengrui Pharma's revenue for the first three quarters of 2025?
Hengrui Pharma reported a revenue of RMB23.20 billion for the first three quarters of 2025.
What is the percentage increase in Hengrui's net profit?
Hengrui's net profit saw a 24.50% increase compared to the same period last year.
How many new drug applications did Hengrui submit?
Hengrui Pharma submitted eight new drug applications during this period.
What breakthrough drug development programs did Hengrui achieve?
Four of Hengrui's programs received a breakthrough therapy designation, highlighting their potential.
What was Hengrui's presence at ESMO 2025?
Hengrui presented 46 oncology studies, including nine oral presentations at ESMO 2025 in Berlin.
